PPLPHARMA Q1 FY27 results at a glance
PIRAMAL PHARMA LIMITED Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹2,270 cr |
|---|
| Revenue YoY | +17.4% |
|---|
| Operating profit | -₹28.35 cr |
|---|
| Operating margin | -1.2% |
|---|
| Net profit | -₹69.39 cr |
|---|
| Net profit YoY | +15.1% |
|---|
| Net profit QoQ | -686.7% |
|---|
| Net margin | -3.1% |
|---|
| Basic EPS | ₹-0.52 |
|---|
| TTM revenue | ₹9,095 cr |
|---|
| TTM net profit | -₹296 cr |
|---|
| TTM net margin | -3.3% |
|---|
PPLPHARMA Q1 FY27 results: what the numbers say
PIRAMAL PHARMA LIMITED (PPLPHARMA) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹2,270 cr and a net profit of -₹69.39 cr, translating into earnings per share of ₹-0.52.
Compared with the same quarter a year earlier, revenue grew by +17.4% and net profit grew by +15.1%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at -₹28.35 cr, an operating margin of -1.2% versus -4.7% a year ago — a gain of 3.4 percentage points.
PPLPHARMA quarter-wise results table
Revenue
₹2,270 cr
+17.4% YoY
Net profit
-₹69.39 cr
+15.1% YoY
Operating profit
-₹28.35 cr
+68.7% YoY
PIRAMAL PHARMA LIMITED (PPLPHARMA) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹2,270 cr | -₹28.35 cr | -₹69.39 cr | -1.2% | -3.1% | ₹-0.52 | +15.1% | -686.7% |
| Q4 FY262026-03-31 | ₹2,752 cr | ₹242 cr | -₹8.82 cr | 8.8% | -0.3% | ₹-0.07 | -105.7% | +93.5% |
| Q3 FY262025-12-31 | ₹2,140 cr | -₹17.01 cr | -₹136 cr | -0.8% | -6.4% | ₹-1.03 | — | -66.7% |
| Q1 FY262025-06-30 | ₹1,934 cr | -₹90.58 cr | -₹81.7 cr | -4.7% | -4.2% | ₹-0.62 | — | -153.2% |
| Q4 FY252025-03-31 | ₹2,754 cr | ₹318 cr | ₹154 cr | 11.6% | 5.6% | ₹1.16 | — | — |
| TTM (last 4 quarters) | ₹9,095 cr | ₹106 cr | -₹296 cr | 1.2% | -3.3% | ₹-2.24 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
PPLPHARMA quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
PIRAMAL PHARMA LIMITED quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹2,270 cr | ₹2,752 cr | ₹2,140 cr | ₹1,934 cr | ₹2,754 cr |
|---|
| Total expenses | ₹2,298 cr | ₹2,510 cr | ₹2,157 cr | ₹2,024 cr | ₹2,436 cr |
|---|
| Gross profit | ₹1,418 cr | ₹1,696 cr | ₹1,354 cr | ₹1,240 cr | ₹1,799 cr |
|---|
| Operating profit (EBIT) | -₹28.35 cr | ₹242 cr | -₹17.01 cr | -₹90.58 cr | ₹318 cr |
|---|
| Operating margin | -1.2% | 8.8% | -0.8% | -4.7% | 11.6% |
|---|
| Interest cost | ₹88.08 cr | ₹82.99 cr | ₹89.24 cr | ₹86.15 cr | ₹104 cr |
|---|
| Profit before tax | -₹7.46 cr | ₹43 cr | -₹93.86 cr | -₹79.02 cr | ₹273 cr |
|---|
| Tax expense | ₹61.93 cr | ₹51.83 cr | ₹42.33 cr | ₹2.68 cr | ₹119 cr |
|---|
| Effective tax rate | -830.2% | 120.5% | -45.1% | -3.4% | 43.7% |
|---|
| Net profit (PAT) | -₹69.39 cr | -₹8.82 cr | -₹136 cr | -₹81.7 cr | ₹154 cr |
|---|
| Net profit margin | -3.1% | -0.3% | -6.4% | -4.2% | 5.6% |
|---|
| Basic EPS | ₹-0.52 | ₹-0.07 | ₹-1.03 | ₹-0.62 | ₹1.16 |
|---|
| Diluted EPS | ₹-0.52 | ₹-0.07 | ₹-1.03 | ₹-0.62 | ₹1.16 |
|---|
PPLPHARMA results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +17.4% | -0.1% | — | — | — |
|---|
| Revenue QoQ | -17.5% | +28.6% | +10.7% | -29.8% | — |
|---|
| Operating profit YoY | +68.7% | -23.9% | — | — | — |
|---|
| Operating profit QoQ | -111.7% | +1523.5% | +81.2% | -128.5% | — |
|---|
| Net profit YoY | +15.1% | -105.7% | — | — | — |
|---|
| Net profit QoQ | -686.7% | +93.5% | -66.7% | -153.2% | — |
|---|
| EPS YoY | +16.1% | -106.0% | — | — | — |
|---|
| EPS QoQ | -642.9% | +93.2% | -66.1% | -153.4% | — |
|---|
PPLPHARMA annual results history
Full-year performance for PIRAMAL PHARMA LIMITED, useful for reading each quarter in context.
PIRAMAL PHARMA LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹8,759 cr | ₹9,061 cr | ₹8,106 cr | ₹7,032 cr |
|---|
| Total expenses | ₹8,604 cr | ₹8,382 cr | ₹7,644 cr | ₹7,080 cr |
|---|
| Gross profit | ₹5,175 cr | ₹5,489 cr | ₹4,848 cr | ₹4,032 cr |
|---|
| Operating profit (EBIT) | ₹155 cr | ₹679 cr | ₹462 cr | -₹47.97 cr |
|---|
| Operating margin | 1.8% | 7.5% | 5.7% | -0.7% |
|---|
| Interest cost | ₹338 cr | ₹418 cr | ₹447 cr | ₹338 cr |
|---|
| Profit before tax | -₹176 cr | ₹415 cr | ₹179 cr | -₹120 cr |
|---|
| Tax expense | ₹150 cr | ₹324 cr | ₹161 cr | ₹66.31 cr |
|---|
| Effective tax rate | -85.1% | 78.0% | 90.1% | -55.2% |
|---|
| Net profit (PAT) | -₹326 cr | ₹91.13 cr | ₹17.82 cr | -₹186 cr |
|---|
| Net profit margin | -3.7% | 1.0% | 0.2% | -2.7% |
|---|
| Basic EPS | ₹-2.46 | ₹0.69 | ₹0.14 | ₹-1.54 |
|---|
| Diluted EPS | ₹-2.46 | ₹0.69 | ₹0.14 | ₹-1.54 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹2,270 cr against ₹1,934 cr in Q1 FY26, and ₹2,752 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -17.5%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹2,298 cr, or 101.2% of revenue, with operating profit grew +68.7% year on year.
Margins, tax and profitability
Net profit of -₹69.39 cr works out to a net margin of -3.1% compared with -4.2% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, PIRAMAL PHARMA LIMITED reported profit before tax of -₹7.46 cr, a tax charge of ₹61.93 cr (effective rate -830.2%), interest cost of ₹88.08 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from -₹8.82 cr in Q4 FY26 to -₹69.39 cr in Q1 FY27, a change of -686.7%.
Trailing twelve months and annual context
Across the trailing four quarters PIRAMAL PHARMA LIMITED has generated revenue of ₹9,095 cr and net profit of -₹296 cr, a trailing net margin of -3.3%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹8,759 cr with net profit of -₹326 cr and EPS of ₹-2.46, versus the prior year where revenue declined -3.3% and profit declined -457.7%.
What to watch in the next PPLPHARMA quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
PIRAMAL PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
PPLPHARMA results coverage
No results report published for PPLPHARMA yet — our desk covers each quarter within minutes of the filing.
PPLPHARMA quarterly results FAQs
What were PIRAMAL PHARMA LIMITED (PPLPHARMA) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), PIRAMAL PHARMA LIMITED reported revenue of ₹2,270 cr and net profit of -₹69.39 cr, a change of +15.1% year on year on +17.4% revenue growth. EPS stood at ₹-0.52.
What is PPLPHARMA profit margin in Q1 FY27?
PIRAMAL PHARMA LIMITED posted a net profit margin of -3.1% and an operating margin of -1.2% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹9,095 cr and net profit -₹296 cr.
Did PPLPHARMA results beat the previous quarter?
PIRAMAL PHARMA LIMITED net profit changed -686.7% quarter on quarter, from -₹8.82 cr in Q4 FY26 to -₹69.39 cr in Q1 FY27.
When are PIRAMAL PHARMA LIMITED (PPLPHARMA) quarterly results?
PIRAMAL PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see PPLPHARMA latest quarterly results?
Results coverage for PPLPHARMA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the PPLPHARMA stock page.
What is PIRAMAL PHARMA LIMITED annual revenue and profit?
For FY26, PIRAMAL PHARMA LIMITED reported full-year revenue of ₹8,759 cr and net profit of -₹326 cr, with EPS of ₹-2.46.
How many quarterly results has PPLPHARMA declared recently?
Past results dates for PPLPHARMA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
